Osimertinib with Platinum Based Chemotherapy in Epidermal Growth Factor Receptor (EGFR)-Mutated Metastatic Non Small Cell Lung Cancer (NSCLC) | ||||
| The Medical Journal of Cairo University | ||||
| Volume 93, Issue 03, March 2025, Page 109-114 PDF (98.18 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/mjcu.2025.422786 | ||||
 View on SCiNiTO | ||||
| Author | ||||
| MOHAMED M. FAROUK AKL, M.D. . | ||||
| The Department of Clinical Oncology & Nuclear Medicine, Faculty of Medicine, Mansoura University | ||||
| Abstract | ||||
| Background: Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Evidence suggests that Osimertinib plus chemotherapy may prolong the progression-free survival (PFS) in with EGFR-mu-tated metastatic NSCLC patients. Aim of Study: To assess the efficacy outcome of Osime-rtinib plus platinum-based chemotherapy in EGFR-mutated metastatic NSCLC patients. Patients and Methods: This is a retrospective analysis which included 21 patients with EGFR-mutated metastatic NSCLC, treated with combination therapy of osimertinib at 80 mg once daily plus gemcitabine at 1000mg/m2 on D1 & D8 and carboplatin at an area under the curve 5 given every three weeks for four cycles. Results: The median PFS for patients was 17 months (95% CI 13.5-20.5), while the median OR was 22 months (95% CI 15.9-28.1). The one year PFS was 64%, while the one year OS was 84%. The objective response rate was 76.2%. The com-monest adverse effects, (AEs) were hematologic toxicity. Conclusions: First-line treatment with osimertinib plus chemotherapy offered prolonged PFS in patients with EG-FR-mutated metastatic NSCLC. | ||||
| Keywords | ||||
| NSCLC; EGFR-mutated; Osimertinib; Meta-static | ||||
|
Statistics Article View: 118 PDF Download: 61 |
||||
